Review article: Endocannabinoids and their receptors in the enteric nervous system

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 8, 2005, Pages 667-683

  Duncan, M ^a   Davison, J S ^a   Sharkey, K A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CAPSAICIN; CAPSAZEPINE; CROTON OIL; DEXANABINOL; DEXTRAN SULFATE; DRONABINOL; ENDOCANNABINOID; HEXAMETHONIUM; METHANANDAMIDE; N ARACHIDONYL DOPAMINE; NOLADIN ETHER; OLEAMIDE; PALMIDROL; PLACEBO; RIMONABANT; SEROTONIN 3 RECEPTOR; SULFONIC ACID DERIVATIVE; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; VERATRIDINE; WIN 55940;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTONOMIC NERVOUS SYSTEM; CANCER; CELL ACTIVITY; CLINICAL TRIAL; COLITIS; DIARRHEA; DRUG ANTAGONISM; DRUG INHIBITION; DYSLIPIDEMIA; ENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HUMAN; IMMUNOREACTIVITY; INTERNEURON; INTESTINE INNERVATION; IRRITABLE COLON; MOTONEURON; MULTIPLE SCLEROSIS; MYENTERIC PLEXUS; NEUROTRANSMISSION; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SENSORY NERVE CELL; TOBACCO DEPENDENCE;

ANIMALS; ENDOCANNABINOIDS; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL TRACT; HUMANS; LIGANDS; RATS; RECEPTORS, CANNABINOID;

EID: 26944451293     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02648.x     Document Type: Review

References (155)

1. Grinspoon L, Bakalar JB. Marihuana, the Forbidden Medicine. New Haven, USA: Yale University Press, 1997.
2. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-7.
3. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
4. Munro S, Thomas KL, Abushaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
5. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
6. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoyl-glycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
7. Mechoulam R, Benshabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
8. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001; 48: 859-67.
9. Izzo AA, Mascolo N, Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol 2001; 1: 597-603.
10. Furness JB, Costa M. The Enteric Nervous System. Edinburgh, UK: Churchill-Livingstone, 1987.
11. Hewlett AC, Earth F, Bonner TI, et al. International Union of Pharmacology: XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
12. Shire D, Carillon C, Kaghad M, et al. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 1995; 270: 3726-31.
13. Begg M, Pacher P, Batkai S, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005: 106: 133-45.
14. Pacher P, Batkai S, Kunos G. Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology 2005; 48: 1130-8.
15. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-305.
16. Batkai S, Pacher P, Osei-Hyiaman D, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004; 110: 1996-2002.
17. Ralevic V. Cannabinoid modulation of peripheral autonomic and sensory neurotransmission. Eur J Pharmacol 2003; 472: 1-21.
18. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-31.
19. Griffin G, Fernando SR, Ross RA, et al. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 1997; 339: 53-61.
20. Storr M, Gaffal E, Saur D, Schusdziarra V, Allescher HD. Effect of cannabinoids on neural transmission in rat gastric fundus. Can J Physiol Pharmacol 2002; 80: 67-76.
21. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-80.
22. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452-7.
23. Wiley JL, Martin BR. Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 2002; 121: 57-63.
24. Hillard CJ. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat 2000; 61: 3-18.
25. Sugiura T, Kondo S, Kishimoto S, et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 2000; 275: 605-12.
26. Sugiura T, Kodaka T, Nakane S, et al. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J Biol Chem 1999; 274: 2794-801.
27. Hanus L, Abu-Lafi S, Fride E, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001; 98: 3662-5.
28. Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett 2002; 513: 294-8.
29. Oka S, Tsuchie A, Tokumura A, et al. Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J Neurochem 2003; 85: 1374-81.
30. Bisogno T, Melck D, Bobrov MY, et al. N-acyl-dopamines: novel synthetic CB(I) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000; 351 (Pt 3): 817-24.
31. Calignano A. La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-81.
32. Huang SM, Bisogno T, Trevisani M, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 2002; 99: 8400-5.
33. Leggett JD, Aspley S, Beckett SR, D'Antona AM, Kendall DA, Kendall DA. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 2004; 141: 253-62.
34. Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301: 1020-4.
35. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003; 83: 1017-66.
36. Piomelli D, Giuffrida A, Calignano A, Rodriguez DF. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21: 218-24.
37. Egertova M, Giang DK, Cravatt BF, Elphick MR. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc Biol Sci 1998; 265: 2081-5.
38. Gulyas AI, Cravatt BF, Bracey MH, et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 2004; 20: 441-58.
39. Pacher P, Batkai S, Osei-Hyiaman D, et al. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 2005; 289: H533-41.
40. Dinh TP, Freund TF, Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 2002; 121: 149-58.
41. Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81.
42. Lichtman AH, Hawkins EG, Griffin G, Cravatt BF. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 2002; 302: 73-9.
43. Katayama K, Ueda N, Kurahashi Y, Suzuki H, Yamamoto S, Kato I. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim Biophys Acta 1997; 1347: 212-8.
44. Ueda N. Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat 2002; 68-69: 521-34.
45. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 2002; 99: 10819-24.
46. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-84.
47. Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A 2003; 100: 4269-74.
48. Hewlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47 (Suppl. 1): 345-58.
49. Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 2002; 68: 247-86.
50. Hirasawa M, Schwab Y, Natah S, et al. Dendritically released transmitters cooperate via autocrine and retrograde actions to inhibit afferent excitation in rat brain. J Physiol (Lond) 2004; 559: 611-24.
51. Ahluwalia J, Yaqoob M, Urban L, Bevan S, Nagy I. Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. J Neurochem 2003; 84: 585-91.
52. 2+-induced relaxation. J Pharmacol Exp Ther 1999; 289: 245-50.
53. Deutsch DG, Goligorsky MS, Schmid PC, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997; 100: 1538-46.
54. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun 1998; 243: 838-43.
55. Mechoulam R, Fride E, Ben Shabat S, Meiri U, Horowitz M. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol 1998; 362: R1-R3.
56. Pinto L, Izzo AA, Cascio MG, et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002; 123: 227-34.
57. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998; 12: 1035-44.
58. Liu J, Batkai S, Pacher P, et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 2003; 278: 45034-9.
59. Schmid HH. Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem Phys Lipids 2000; 108: 71-87.
60. Panikashvili D, Simeonidou C, Ben Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413: 527-31.
61. Skaper SD, Buriani A, Dal Toso R, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A 1996; 93: 3984-9.
62. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 2004; 129: 743-50.
63. Maccarrone M, Finazzi-Agro A. Anandamide hydrolase: a guardian angel of human reproduction? Trends Pharmacol Sci 2004; 25: 353-7.
64. Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001; 134: 563-70.
65. Furness JB. Types of neurons in the enteric nervous system. J Auton Nerv Syst 2000; 81: 87-96.
66. Costa M, Brookes SJ, Hennig GW. Anatomy and physiology of the enteric nervous system. Gut 2000; 47 (Suppl. 4): iv15-9.
67. Brown DR, Timmermans JP. Lessons from the porcine enteric nervous system. Neurogastroenterol Motil 2004; 16 (Suppl. 1): 50-4.
68. Schemann M, Neunlist M. The human enteric nervous system. Neurogastroenterol Motil 2004; 16: 55-9.
69. Galligan JJ. Pharmacology of synaptic transmission in the enteric nervous system. Curr Opin Pharmacol 2002; 2: 623-9.
70. Furness JB, Clerc N, Vogalis F, Stebbing MJ. The enteric nervous system and its extrinsic connections. In: Yamada, T, Alpers, DH, Kaplowitz, N, Laine, L, Owyang, C, Powell, DW, eds. Textbook of Gastroenterology. Philadelphia, USA: Lippincott Williams & Wilkins, 2003: 12-33.
71. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S. Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 2002; 448: 410-22.
72. Kulkarni-Narla A, Brown DR. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 2000; 302: 73-80.
73. Coutts AA, Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 1997; 121: 1557-66.
74. Sones WR, Demuth DG, Makwana R, Parsons ME, Molleman A. Cannabinoid modulation of nicotine responses in guinea-pig ileum myenteric neurons. Br J Pharmacol 2004 (available at: http://www.pa2online.org/Vol2Issue4abst005P.html) (accessed 1 September 2005).
75. Lopez-Redondo F, Lees GM, Pertwee RG. Effects of cannabinoid receptor ligands on electrophysiological properties of myenteric neurones of the guinea-pig ileum. Br J Pharmacol 1997; 122: 330-4.
76. Demuth D, Parsons ME, Molleman A. Cannabinoid-mediated inhibition of nicotinic Ach currents in myenteric neurons. 2005. 14th Symposium on Cannabinoids, International Cannabinoid Research Society (available at: http://www.cannabinoidsociety.org) (accessed 1 September 2005).
77. Heinemann A, Shahbazian A, Holzer P. Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology 1999; 38: 1289-97.
78. Landi M, Croci T, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Manara L. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors. Eur J Pharmacol 2002; 450: 77-83.
79. Izzo AA, Mascolo N, Capasso R, Germanó MP, De Pasquale R, Capasso F. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedeberg's Arch Pharmacol 1999; 360: 221-3.
80. Storr M, Sibaev A, Marsicano G, et al. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am J Physiol Gastrointest Liver Physiol 2004: 286: G110-7.
81. Vanner S, MacNaughton WK. Submucosal secretomotor and vasodilator reflexes. Neurogastroenterol Motil 2004; 16 (Suppl. 1): 39-43.
82. MacNaughton WK, Van Sickle MD, Keenan CM, Cushing K, Mackie K, Sharkey KA. Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am J Physiol Gastrointest Liver Physiol 2004; 286: G863-71.
83. Tyler K, Hillard CJ, Greenwood-Van Meerveld B. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Eur J Pharmacol 2000; 409: 207-11.
84. Makwana R, Molleman A, Parsons ME. Cannabinoid inhibition of pharmacologically evoked electrogenic secretory function of the rat proximal colon. Br J Pharmacol 2004 (available at: http://www.pa2online.org/ Vol2Issue4abst034P.html) (accessed 1 September 2005).
85. Furness JB, Jones C, Nurgali K, Clerc N. Intrinsic primary afferent neurons and nerve circuits within the intestine. Prog Neurobiol 2004; 72: 143-64.
86. Berthoud HR, Blackshaw LA, Brookes SJ, Grundy D. Neuroanatomy of extrinsic afferents supplying the gastrointestinal tract. Neurogastroenterol Motil 2004; 16 (Suppl. 1): 28-33.
87. Adami M, Frati P, Bertini S, et al. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br J Pharmacol 2002; 135: 1598-606.
88. Derbenev AV, Stuart TC, Smith BN. Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve. J Physiol (Lond) 2004; 559: 923-38.
89. Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA. Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 2003; 285: G566-76.
90. Putzer T, Niederhoffer N, Szabo B. Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system. Naunyn Schmiedeberg's Arch Pharmacol 2005; 371: 9-17.
91. Randall MD, Harris D, Kendall DA, Ralevic V. Cardiovascular effects of cannabinoids. Pharmacol Ther 2002; 95: 191-202.
92. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004; 24: 2708-15.
93. Partosoedarso ER, Abrahams TP, Scullion RT, Moerschbaecher JM, Hornby PJ. Cannabinoidl receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol (Lond) 2003; 550: 149-58.
94. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-7.
95. Holzer P. Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. Eur J Pharmacol 2001; 429: 177-93.
96. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999; 92: 1171-5.
97. Coutts AA, Izzo AA. The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 2004; 4: 572-9.
98. Van Sickle MD, Oland LD, Ho W, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001; 121: 767-74.
99. Izzo AA, Pinto L, Borrelli F, Capasso R, Mascolo N, Capasso F. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 2000; 129: 1627-32.
100. Mancinelli R, Fabrizi A, Del Monaco S, et al. Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse. Life Sci 2001; 69: 101-11.
101. Smart D, Gunthorpe MJ, Jerman JC, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 2000; 129: 227-30.
102. Izzo AA, Capasso R, Pinto L, Di Carlo G, Mascolo N, Capasso F. Effect of vanilloid drugs on gastrointestinal transit in mice. Br J Pharmacol 2001; 132: 1411-6.
103. Lehmann A, Blackshaw LA, Branden L, et al. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 2002; 123: 1129-34.
104. Vakil N. Review article: New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 19: 1041-9.
105. Coruzzi G, Adami M, Coppelli G, Frati P, Soldani G. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedeberg's Arch Pharmacol 1999; 360: 715-8.
106. Mathison R, Ho W, Pittman QJ, Davison JS, Sharkey KA. Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 2004; 142: 1247-54.
107. Klein TW, Newton C, Larsen K, et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003; 74: 486-96.
108. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004; 113: 1202-9.
109. Fernandez JR, Allison DB. Rimonabant Sanofi-Synthelabo. Curr Opin Investig Drugs 2004; 5: 430-5.
110. Sanofi Avenus. Available at: http://www.sanofl-adventis. com (accessed 1 September 2005).
111. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005; 76: 1307-24.
112. Chaytor AT, Martin PE, Evans WH, Randall MD, Griffith TM. The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol (Lond) 1999; 520 (Pt 2): 539-50.
113. Kunos G, Pacher P. Cannabinoids cool the intestine. Nat Med 2004; 10: 678-9.
114. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 377-91.
115. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 1999; 51: 159-212.
116. Patterson LM, Zheng H, Ward SM, Berthoud HR. Vanilloid receptor (VR1) expression in vagal afferent neurons innervating the gastrointestinal tract. Cell Tissue Res 2003; 311: 277-87.
117. Holzer P. TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur J Pharmacol 2004; 500: 231-41.
118. Ward SM, Bayguinov J, Won KJ, Grundy D, Berthoud HR. Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract. J Comp Neurol 2003; 465: 121-35.
119. Anavi-Goffer S, McKay NG, Ashford ML, Courts AA. Vanilloid receptor type 1-immunoreactivity is expressed by intrinsic afferent neurones in the guinea-pig myenteric plexus. Neurosci Lett 2002; 319: 53-7.
120. Poonyachoti S, Kulkarni-Narla A, Brown DR. Chemical coding of neurons expressing delta- and kappa-opioid receptor and type I vanilloid receptor immunoreactivities in the porcine ileum. Cell Tissue Res 2002; 307: 23-33.
121. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 2000; 100: 685-8.
122. Ahluwalia J, Urban L, Bevan S, Nagy I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 2003; 17: 2611-8.
123. Hermann H, De Petrocellis L, Bisogno T, Schiano MA, Lutz B, Di Marzo V. Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol Life Sci 2003; 60: 607-16.
124. Millns PJ, Chapman V, Kendall DA. Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones. Br J Pharmacol 2001; 132: 969-71.
125. Duncan M, Millns P, Smart D, Wright JE, Kendall DA, Ralevic V. Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor. Br J Pharmacol 2004; 142: 509-18.
126. Jordt SE, Bautista DM, Chuang HH, et al. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 2004; 427: 260-5.
127. Zygmunt PM, Andersson DA, Hogestatt ED. Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 2002; 22: 4720-7.
128. McVey DC, Schmid PC, Schmid HH, Vigna SR. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J Pharmacol Exp Ther 2003; 304: 713-22.
129. Pacher P, Batkai S, Kunos G. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol (Lond) 2004; 558: 647-57.
130. Geppetti P, Trevisani M. Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function. Br J Pharmacol 2004; 141: 1313-20.
131. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004; 74: 1317-24.
132. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004; 16 (Suppl. 2): 17-28.
133. Kulkarni-Narla A, Brown DR. Opioid, cannabinoid and vanilloid receptor localization on porcine cultured myenteric neurons. Neurosci Lett 2001; 308: 153-6.
134. Barann M, Molderings G, Bruss M, Bonisch H, Urban BW, Gothert M. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 2002; 137: 589-96.
135. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995; 73: 907-10.
136. Humphrey PP, Bountra C, Clayton N, Kozlowski K. Review article: The therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13 (Suppl. 2): 31-8.
137. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-55.
138. Gunput MD. Review article: Clinical pharmacology of alosetron. Aliment Pharmacol Ther 1999; 13 (Suppl. 2): 70-6.
139. Fride E, Feigin C, Ponde DE, et al. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur J Pharmacol 2004; 506: 179-88.
140. GW Pharmaceuticals plc. Available at: http://www. gwpharm.com/ research_pipeline.asp (accessed 1 September 2005).
141. Showalter VM, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996; 278: 989-99.
142. Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995; 48: 443-50.
143. Huffman JW, Liddle J, Yu S, et al. 3-(1′,1′-Dimethylbutyl)-1- deoxy-[Delta]8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 1999; 7: 2905-14.
144. Ross RA, Gibson TM, Brockie HC, et al. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 2001; 132: 631-40.
145. Lin SY, Khanolkar AD, Fan PS, et al. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem 1998; 41: 5353-61.
146. Rinaldi-Carmona M, Barth F, Millan J, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284: 644-50.
147. Izzo AA, Mascolo N, Borrelli F, Capasso F. Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Br J Pharmacol 1998; 124: 1363-8.
148. Mang CF, Erbelding D, Kilbinger H. Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br J Pharmacol 2001; 134: 161-7.
149. Izzo AA, Mascolo N, Tonini M, Capasso F. Modulation of peristalsis by cannabinoid CB(1) ligands in the isolated guinea-pig ileum. Br J Pharmacol 2000; 129: 984-90.
150. Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 1999; 384: 37-42.
151. Krowicki ZK, Moerschbaecher JM, Winsauer PJ, Digavalli SV, Hornby PJ. Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol 1999; 371: 187-96.
152. Carai MA, Colombo G, Cessa GL. Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR 141716 (Rimonabant). Eur J Pharmacol 2004; 494: 221-4.
153. Colombo G, Agabio R, Lobina C, Reali R, Cessa GL. Cannabinoid modulation of intestinal propulsion in mice. Eur J Pharmacol 1998; 344: 67-9.
154. Croci T, Manara L, Aureggi G, et al. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol 1998; 125: 1393-5.
155. Manara L, Croci T, Guagnini F, et al. Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Dig Liver Dis 2002; 34: 262-9.